Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fase 2-platformsundersøgelse af nye immunterapikombinationer hos deltagere med tidligere ubehandlet, avanceret/metastatisk ikke-småcellet lungekræft

6. november 2026 opdateret af: GlaxoSmithKline

Et fase 2, randomiseret, åbent platformsstudie, der anvender en masterprotokol til at evaluere nye immunterapikombinationer hos deltagere med tidligere ubehandlet, lokalt avanceret/metastatisk, programmeret dødsligand 1-selekteret ikke-småcellet lungekræft

This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

351

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Buenos Aires, Argentina, C1426ABP
        • GSK Investigational Site
      • Cipoletti Rio Negro, Argentina, R8324CVE
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aire, Argentina, C1426AGE
        • GSK Investigational Site
      • Florida, Argentina, 1602
        • GSK Investigational Site
      • Mar del Plata, Argentina, 7600
        • GSK Investigational Site
      • San Juan, Argentina, J5402DIL
        • GSK Investigational Site
      • Santa Fe, Argentina, 3000
        • GSK Investigational Site
      • Wilrijk, Belgien, 2650
        • GSK Investigational Site
      • Barretos, Brasilien, 14784-400
        • GSK Investigational Site
      • Porto Alegre, Brasilien, 90610-000
        • GSK Investigational Site
      • São Paulo, Brasilien, 01246-000
        • GSK Investigational Site
      • Vitória, Brasilien, 29043-260
        • GSK Investigational Site
      • Middlesbrough, Det Forenede Kongerige, TS4 3BW
        • GSK Investigational Site
      • Wolverhampton, Det Forenede Kongerige, WV10 0QP
        • GSK Investigational Site
    • Middlesex
      • Northwood, Middlesex, Det Forenede Kongerige, HA6 2RN
        • GSK Investigational Site
      • Oulu, Finland, 90220
        • GSK Investigational Site
      • Tampere, Finland, 33520
        • GSK Investigational Site
      • Turku, Finland, 20520
        • GSK Investigational Site
      • Vaasa, Finland, 65130
        • GSK Investigational Site
      • Abu Dhabi, Forenede Arabiske Emirater
        • GSK Investigational Site
      • Abu Dhabi, Forenede Arabiske Emirater, 51900
        • GSK Investigational Site
    • Florida
      • Plantation, Florida, Forenede Stater, 33322-5426
        • GSK Investigational Site
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87131
        • GSK Investigational Site
    • Tennessee
      • Chattanooga, Tennessee, Forenede Stater, 37404
        • GSK Investigational Site
    • West Virginia
      • Morgantown, West Virginia, Forenede Stater, 26506
        • GSK Investigational Site
      • Bordeaux, Frankrig, 33076
        • GSK Investigational Site
      • Caen, Frankrig, 14033
        • GSK Investigational Site
      • Marseille, Frankrig, 13009
        • GSK Investigational Site
      • Quimper, Frankrig, 29107
        • GSK Investigational Site
      • Strasbourg, Frankrig, 67091
        • GSK Investigational Site
      • Athens, Grækenland, 11528
        • GSK Investigational Site
      • Pylaia Thessaloniki, Grækenland, 57001
        • GSK Investigational Site
      • Thessaloniki, Grækenland, 54645
        • GSK Investigational Site
    • Attica
      • Athens, Attica, Grækenland, 115 27
        • GSK Investigational Site
      • Chaïdári, Attica, Grækenland, 124 62
        • GSK Investigational Site
    • Central Macedonia
      • Thessaloniki, Central Macedonia, Grækenland, 570 10
        • GSK Investigational Site
    • Thessaly
      • Larissa, Thessaly, Grækenland, 411 10
        • GSK Investigational Site
      • Enschede, Holland, 7512 KZ
        • GSK Investigational Site
      • Groningen, Holland, 9728 NZ
        • GSK Investigational Site
      • Leeuwarden, Holland, 8934 AD
        • GSK Investigational Site
      • Utrecht, Holland, 3543 AZ
        • GSK Investigational Site
      • Avellino, Italien, 83100
        • GSK Investigational Site
      • Bergamo, Italien, 24125
        • GSK Investigational Site
      • Pisa, Italien, 57124
        • GSK Investigational Site
      • Verona, Italien, 37045
        • GSK Investigational Site
    • GE
      • Genova, GE, Italien, 16132
        • GSK Investigational Site
      • Chiba, Japan, 277-8577
        • GSK Investigational Site
      • Fukuoka, Japan, 812-8582
        • GSK Investigational Site
      • Hyōgo, Japan, 673-8558
        • GSK Investigational Site
      • Kanagawa, Japan, 241-8515
        • GSK Investigational Site
      • Osaka, Japan, 590-0197
        • GSK Investigational Site
      • Saitama, Japan, 350-1298
        • GSK Investigational Site
      • Guadajalara, Mexico, 44280
        • GSK Investigational Site
      • San Luis Potosí City, Mexico, 78209
        • GSK Investigational Site
      • Lublin, Polen, 20-954
        • GSK Investigational Site
      • Prabuty, Polen, 82-550
        • GSK Investigational Site
      • Siedlce, Polen, 08-110
        • GSK Investigational Site
      • Guimarães, Portugal, 4835-044
        • GSK Investigational Site
      • Lisbon, Portugal, 1500-650
        • GSK Investigational Site
      • Lisbon, Portugal, 1998-018
        • GSK Investigational Site
      • Porto, Portugal, 4200-072
        • GSK Investigational Site
      • Vila Nova de Gaia, Portugal, 4434-502
        • GSK Investigational Site
      • Badajoz, Spanien, 06080
        • GSK Investigational Site
      • Barcelona, Spanien, 08035
        • GSK Investigational Site
      • Las Palmas de Gran Canar, Spanien, 35016
        • GSK Investigational Site
      • Madrid, Spanien, 28041
        • GSK Investigational Site
      • Madrid, Spanien, 28046
        • GSK Investigational Site
      • Madrid, Spanien, 28027
        • GSK Investigational Site
      • Málaga, Spanien, 29010
        • GSK Investigational Site
      • PamplonaNavarra, Spanien, 28027
        • GSK Investigational Site
      • Valencia, Spanien, 46026
        • GSK Investigational Site
      • Valencia, Spanien, 46009
        • GSK Investigational Site
    • Barcelona
      • Badalona, Barcelona, Spanien, 08916
        • GSK Investigational Site
      • L'Hospitalet de Llobregat, Barcelona, Spanien, 08907
        • GSK Investigational Site
      • Cape Town, Sydafrika, 7570
        • GSK Investigational Site
      • Parktown, Sydafrika, 2193
        • GSK Investigational Site
      • Incheon, Sydkorea, 21565
        • GSK Investigational Site
      • Seoul, Sydkorea, 03080
        • GSK Investigational Site
      • Seoul, Sydkorea, 03722
        • GSK Investigational Site
      • Suwon Gyeonggi-do, Sydkorea, 442-723
        • GSK Investigational Site
      • Bangkok, Thailand, 10210
        • GSK Investigational Site
      • Chiang Mai, Thailand, 50200
        • GSK Investigational Site
      • Kho Hong Hat Yai, Thailand, 90110
        • GSK Investigational Site
      • Khon Kaen, Thailand, 40002
        • GSK Investigational Site
      • Pathum Thani, Thailand, 12120
        • GSK Investigational Site
      • Ankara, Tyrkiet (Türkiye), 06800
        • GSK Investigational Site
      • Ankara, Tyrkiet (Türkiye), 06680
        • GSK Investigational Site
      • Antalya, Tyrkiet (Türkiye), 07070
        • GSK Investigational Site
      • Istanbul, Tyrkiet (Türkiye), 34214
        • GSK Investigational Site
    • Atakum
      • Samsun, Atakum, Tyrkiet (Türkiye), 55200
        • GSK Investigational Site
      • Berlin, Tyskland, 13125
        • GSK Investigational Site
      • Heidelberg, Tyskland, 69126
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Tyskland, 45147
        • GSK Investigational Site
    • Schleswig-Holstein
      • Großhansdorf, Schleswig-Holstein, Tyskland, 22927
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Tyskland, 07747
        • GSK Investigational Site
      • Budapest, Ungarn, H-1121
        • GSK Investigational Site
      • Gyöngyös, Ungarn, 3200
        • GSK Investigational Site
      • Tatabánya, Ungarn, 2800
        • GSK Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
  • No prior systemic therapy for their locally advanced or metastatic NSCLC
  • Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
  • PD-L1-high (TC/TPS >= 50%) tumor
  • Measurable disease based on RECIST 1.1, as determined by the investigator
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Adequate Baseline organ function
  • Female participants of childbearing potential must use adequate contraception

Exclusion Criteria:

  • Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
  • Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
  • Received prior therapy with any immune checkpoint inhibitors
  • Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
  • Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
  • Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
  • Autoimmune disease or syndrome that required systemic treatment within the past 2 years
  • Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
  • Received any live vaccine <= 30 days prior to first dose of study intervention
  • Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
  • History or evidence of cardiac abnormalities
  • Current unstable liver or biliary disease
  • Severe infection within 4 weeks prior to the first dose of study intervention
  • Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
  • Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
  • Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
  • Has a history of allogeneic tissue/stem cell transplant or solid organ transplant

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Pembrolizumab Monotherapy

Participants will be administered with pembrolizumab as monotherapy in a fixed dose.

Pembrolizumab will be administered.

Eksperimentel: Dostarlimab Monotherapy

Participants will be administered with dostarlimab as monotherapy in a fixed dose.

Dostarlimab will be administered

Andre navne:
  • GSK4057190
Eksperimentel: Substudy 1A

Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A).

Belrestotug will be administered.

Andre navne:
  • EOS884448
  • GSK4428859A

Dostarlimab will be administered

Andre navne:
  • GSK4057190
Eksperimentel: Substudy 1B

Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B).

Belrestotug will be administered.

Andre navne:
  • EOS884448
  • GSK4428859A

Dostarlimab will be administered

Andre navne:
  • GSK4057190
Eksperimentel: Substudy 1C

Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C).

Belrestotug will be administered.

Andre navne:
  • EOS884448
  • GSK4428859A

Dostarlimab will be administered

Andre navne:
  • GSK4057190
Eksperimentel: Substudy 2A

Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug

Belrestotug will be administered.

Andre navne:
  • EOS884448
  • GSK4428859A

Nelistotug will be administered.

Andre navne:
  • GSK6097608

Dostarlimab will be administered

Andre navne:
  • GSK4057190

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Antal deltagere med behandling fremkommende bivirkninger (TEAE'er) og alvorlige bivirkninger (SAES)
Tidsramme: Op til 228 uger
Op til 228 uger
Antal deltagere med TEAES eller SAES, der fører til dosismodifikationer eller seponering af behandling
Tidsramme: Op til 228 uger
Op til 228 uger

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: GSK Clinical Trials, GlaxoSmithKline

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. oktober 2022

Primær færdiggørelse (Faktiske)

26. oktober 2026

Studieafslutning (Anslået)

6. december 2027

Datoer for studieregistrering

Først indsendt

30. september 2022

Først indsendt, der opfyldte QC-kriterier

30. september 2022

Først opslået (Faktiske)

4. oktober 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 213824
  • 2021-005115-32 (EudraCT nummer)
  • GALAXIES LUNG-201 (Anden identifikator: Study Identifier)
  • 2023 (U.S. NIH-bevilling/kontrakt)
  • 2023-505057-40-00 (Registry Identifier: CTIS (EU))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD-delingsadgangskriterier

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .